Yeast Platform Turns Antimicrobial Peptides into Self-Assembling Nanoparticles

Antimicrobial peptides, short amino acid chains that can punch lethal holes in bacterial membranes, have long been touted as one of the most promising answers to the growing crisis of antibiotic resistance. Yet the promise has repeatedly collided with a stubborn practical problem: making enough of these molecules, cheaply and safely, to test and eventually manufacture them at scale. Extracting them from the organisms that produce them naturally yields tiny amounts, chemical synthesis becomes prohibitively expensive as quantities grow, and the bacteria that biotechnologists usually rely on for recombinant protein production are themselves vulnerable to the very peptides they are being asked to make. A new study published in Applied Microbiology and Biotechnology offers a way around this bottleneck, using the methylotrophic yeast Pichia pastoris as a production host and fusing the peptides to a self-assembling polypeptide that packages them into nanoparticles.

The research, led by Eddie Guillermo Sanchez-Rueda and colleagues at the Laboratory of Biomolecular Engineering and Bionanotechnology of the Institute of Chemistry at the National Autonomous University of Mexico, focused on two well-characterized antimicrobial peptides with very different origins. The first, aurein 1.2, is a short amphipathic peptide originally described from the skin secretions of Australian tree frogs, known for disrupting bacterial membranes. The second, myxinidin, is a peptide derived from a fish pathogen, which has attracted attention for its activity against a broad range of Gram-negative bacteria. Both peptides are small, positively charged, and membrane-active, which makes them attractive drug candidates but also makes them difficult guests in a living production cell.

The team’s central design decision was to genetically fuse each peptide to a triblock polypeptide the authors call CSB, a protein-engineering scaffold that self-assembles into nanoparticles. Rather than letting the antimicrobial peptides float freely in the yeast cell, where their membrane-disrupting activity could poison the host and depress yields, the fusion strategy tethers them to a larger, structured carrier. Once the fusion proteins are produced and purified, the CSB block drives the molecules to organize themselves into discrete protein nanoparticles, effectively immobilizing the peptides within a supramolecular architecture. This kind of self-assembling carrier serves a dual purpose: it shields the producing organism during fermentation, and it creates a nanoparticle format that could later be useful for delivery or formulation of the antimicrobial cargo.

Producing the fusion proteins in Pichia pastoris required careful optimization of the fermentation conditions, and this is where much of the study’s practical value lies. Pichia is a workhorse of industrial biotechnology, prized for its ability to grow to very high cell densities and for a strong, tightly regulated promoter that responds to methanol. The researchers systematically varied the concentrations of glycerol, used as a carbon source for building biomass, and methanol, used to induce expression of the recombinant genes, along with the pH of the culture medium. The outcome of these experiments was strikingly clear: the single most important factor was allowing the yeast to accumulate extensive biomass before the methanol induction was triggered, combined with letting the medium acidify to a permissive pH of approximately 3.

Under those optimized conditions, the gains were dramatic. The aurein 1.2–CSB fusion, abbreviated Aur-CSB, increased in yield by up to 35.3-fold, reaching 35.95 plus or minus 19.05 milligrams per liter of culture. The myxinidin–CSB fusion, Myx-CSB, showed a more modest but still substantial improvement of up to 5.5-fold, reaching 12.96 plus or minus 5.75 milligrams per liter. The difference between the two constructs is itself informative, because it illustrates a familiar reality of recombinant protein production: even two peptides of similar size and function can behave very differently once fused to the same carrier, and yields must be tuned construct by construct rather than assumed from a general protocol.

After purification, the critical question was whether the fusion proteins actually did what the design intended: assemble into nanoparticles. The researchers turned to two complementary biophysical techniques to find out. Atomic force microscopy, which scans a sharp probe across a surface to map its topography with nanometer resolution, and dynamic light scattering, which infers particle size from fluctuations in scattered laser light, both confirmed self-assembly. Interestingly, the three constructs adopted different morphologies. The bare CSB polypeptide formed rod-shaped nanoparticles with an average height of 3.55 plus or minus 0.38 nanometers, while both the Aur-CSB and Myx-CSB fusions formed globular particles, with average heights of 9.79 plus or minus 1.56 nanometers and 9.28 plus or minus 0.99 nanometers respectively. The attached antimicrobial peptides thus appear to influence not just the yield but the geometry of the assembled structures.

With the nanoparticles in hand, the team moved to a preliminary test of biological function, using Escherichia coli as the target organism. Rather than relying on a single assay, they combined fluorescent probes that report on different aspects of bacterial health. A live/dead viability test based on SYTO 9 and propidium iodide staining was used to assess membrane integrity: SYTO 9 stains all cells green, while propidium iodide, which cannot cross intact membranes, only enters and stains red those cells whose membranes have been compromised. Hoechst dye was used to stain bacterial DNA, providing an additional readout. Both the culture supernatants containing the expressed AMP-CSB fusions and the purified nanoparticles displayed preserved antimicrobial activity in these assays, indicating that the peptides had not lost their membrane-disrupting potency by being locked into the nanoparticle format.

The significance of that last point is hard to overstate. One of the recurring fears in fusion-based production of antimicrobial peptides is that burying the active sequence inside a larger protein or a supramolecular structure will neutralize it, forcing researchers to choose between yield and activity. This study suggests the trade-off can be avoided: the CSB scaffold protects the yeast during production, assembles into defined nanoparticles after purification, and still leaves the antimicrobial function intact enough to compromise E. coli membranes. The authors are careful to frame the activity data as preliminary, and fluorescence-based membrane assays are a first screening step rather than a full pharmacological characterization, but the proof of concept is complete across the whole chain from gene to functional nanoparticle.

The broader context makes the work timely. As multidrug-resistant infections continue to spread, the pipeline for new antibiotics remains thin, and antimicrobial peptides are among the few candidate classes moving from academic labs toward clinical and agricultural applications. What has been missing, in many cases, is a manufacturing route that is scalable, economical, and compatible with the biological activity of the product. Yeast fermentation in Pichia pastoris is already used industrially for enzymes, vaccines, and biopharmaceuticals, so demonstrating that AMP-nanoparticle fusions can be produced there, with yields improved by simple and transferable fermentation parameters, lowers a significant barrier. The finding that high pre-induction biomass and acidic culture conditions around pH 3 boost production is the kind of process knowledge that can be directly adopted by other groups working on similar constructs.

There is also a nanotechnology dimension that extends beyond antibiotics. The CSB triblock polypeptide belongs to a growing family of genetically encoded, self-assembling protein building blocks that can form nanoparticles of controlled shape and size without chemical crosslinkers. Fusing functional peptides to such scaffolds turns the nanoparticles into programmable multivalent display platforms, with potential uses in drug delivery, vaccination, biosensing, and materials science. By showing that the identity of the fused peptide changes the assembly morphology, from rods to globules, the Mexican team has added a data point to the emerging design rules for these systems. The study, which was supported by UNAM-PAPIIT funding and carried out within a doctoral program spanning UNAM and the University of Groningen, establishes key parameters for efficient production of self-assembling AMP-based protein nanoparticles in Pichia pastoris and provides a scalable platform for their further development and functional characterization. If subsequent work confirms and extends the antimicrobial findings to other pathogens, the humble yeast tank could become an unexpected factory for the next generation of nanostructured antibiotics.

Subject of Research: Recombinant production of antimicrobial peptide nanoparticles in Pichia pastoris

Article Title: Production of antimicrobial peptides fused to a nanoparticle-forming polypeptide using Pichia pastoris

Article References: Sanchez-Rueda, E. G., Cruz-Garcia, B. B., Hernandez-Cortes, F. O., Trejo-Perez, M. A., Valentinotti-Bonardi, L., Clairin-Savage, A., Ramírez-Carreto, S., & Hernandez-Garcia, A. (2026). Production of antimicrobial peptides fused to a nanoparticle-forming polypeptide using Pichia pastoris. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14033-3

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14033-3

Keywords: antimicrobial peptides, Pichia pastoris, nanoparticles, self-assembly, recombinant protein production, aurein 1.2, myxinidin, antibiotic resistance, biotechnology, fermentation optimization, atomic force microscopy, E. coli